Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection.

ABSTRACT:

Background

Early recurrence of hepatocellular carcinoma (HCC) is a major obstacle to improving the prognosis, and no widely accepted adjuvant therapy guideline for patients post-liver resection is available. Currently, all available methods and biomarkers are insufficient to accurately predict post-operation HCC patients' risk of early recurrence and their response to adjuvant therapy.

Methods

In this study, we downloaded four gene expression datasets (GSE14520, GSE54236, GSE87630, and GSE109211) from the Gene Expression Omnibus database and identified 34 common differentially expressed genes associated with HCC dysregulation and response to adjuvant sorafenib. Then, we constructed a novel 11-messenger RNA predictive model by using ROC curves analysis, univariate Cox regress

SUBMITTER: Zheng L 

PROVIDER: S-EPMC8628622 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature